Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of “Hold” by Brokerages

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned an average rating of “Hold” from the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $21.25.

Several equities research analysts have commented on the company. Needham & Company LLC restated a “hold” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. BTIG Research reiterated a “buy” rating and issued a $18.00 price target on shares of Evolus in a research note on Monday, September 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research report on Monday. Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, HC Wainwright decreased their price target on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th.

Institutional Trading of Evolus

A number of large investors have recently added to or reduced their stakes in EOLS. Frazier Life Sciences Management L.P. acquired a new stake in Evolus in the 2nd quarter valued at about $22,431,000. Nantahala Capital Management LLC raised its stake in Evolus by 33.2% in the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock valued at $35,163,000 after buying an additional 1,428,931 shares during the period. Soleus Capital Management L.P. lifted its position in shares of Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after buying an additional 1,039,842 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Evolus in the first quarter valued at approximately $12,330,000. Finally, Caligan Partners LP increased its holdings in shares of Evolus by 23.8% during the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after acquiring an additional 796,973 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Up 3.5%

EOLS traded up $0.23 during trading on Friday, hitting $6.85. The company had a trading volume of 1,223,429 shares, compared to its average volume of 1,948,176. The company has a market capitalization of $444.02 million, a PE ratio of -7.45 and a beta of 0.97. Evolus has a one year low of $5.71 and a one year high of $17.12. The firm’s 50-day moving average price is $6.57 and its 200 day moving average price is $8.06.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million during the quarter, compared to analysts’ expectations of $91.23 million. Evolus had a negative return on equity of 759.04% and a negative net margin of 20.49%. Evolus has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Evolus will post -0.61 earnings per share for the current year.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.